par Casado Arroyo, Ruben 
;Abugattas De Torres, Juan Pablo
Référence Revue médicale de Bruxelles, 41, 3, page (175-176)
Publication Publié, 2020-11-01
;Abugattas De Torres, Juan Pablo Référence Revue médicale de Bruxelles, 41, 3, page (175-176)
Publication Publié, 2020-11-01
Article révisé par les pairs
| Résumé : | The choice of antithrombotic treatment for patients with atrial fibrillation who have an acute coronary syndrome or have undergone percutaneous coronary intervention is a challenge today. Oral anticoagulation is indicated for the prevention of stroke and systemic embolism in patients with atrial fibrillation, but it has not been shown to prevent stent thrombosis and is generally not indicated for secondary prevention after acute coronary syndrome. The objective of the AUGUSTUS study was to evaluate the efficacy of Apixaban versus a vitamin K antagonist and aspirin versus placebo against a concomitant treatment with a P2Y12 inhibitor in this specific population. In this context, this randomized study has provided further evidence in favour of Apixaban treatment and Aspirin suppression with respect to the number of ischemic events and rates of major bleeding. |
